Opendata, web and dolomites


Innovative cancer therapy through Myc inhibition: taking OMO-103 to market

Total Cost €


EC-Contrib. €






 MYCure project word cloud

Explore the words cloud of the MYCure project. It provides you a very rough idea of what is the project "MYCure" about.

2023    survival    contrast    builds    models    20    resistance    receptors    compensated    proteins    15    revolutionizing    therapies    despite    cells    market    toxic    companies    licensing    sme    cell    bn    company    treat    breaking    nuclei    rounds    commercialization    deaths    instrument    closed    trials    acumen    patented    excellence    first    pressing    peptomyc    treatments    myc    plan    14    efficient    women    scientific    total    clear    treatment    accounting    103    redundant    penetrate    70    projected    clinical    capitals    toxicity    full    kill    poised    addressable    inhibiting    safer    small    financing    world    men    completing    biotech    lung    share    omo    millions    annually    inhibition    2018    global    foundation    equity    ground    sound    gain    combines    investments    inhibitor    mycure    leadership    attack    too    tumours    innovative    evolve    thanks    2029    class    surface    cancer    pharmaceutical    record    ineffective    considerable    business    venture   

Project "MYCure" data sheet

The following table provides information about the project.


Organization address
postcode: 8035
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 3˙170˙790 €
 EC max contribution 2˙219˙553 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PEPTOMYC SL ES (BARCELONA) coordinator 2˙219˙553.00


 Project objective

Cancer is a global challenge with 9 millions (M) deaths annually and new cases projected to rise by 70% in the 20 years, and there is a clear and pressing need for more effective therapies. In the EU, lung cancer is the most common cancer in men and the third most common in women, with 2 M new cases in 2018 accounting for ~20% of all cancer deaths. Despite considerable recent advances in lung cancer treatment, current treatments are still too often ineffective or highly toxic. Peptomyc is a unique biotech SME that is revolutionizing cancer treatment with its ground-breaking innovative cancer therapies inhibiting Myc. Our patented product OMO-103 is able to penetrate the nuclei, attack Myc and kill cancer cells. In contrast, most current therapies attack redundant cell surface receptors or proteins that can be compensated by tumours, which then evolve resistance. Our company combines scientific excellence with sound business acumen: our scientific leadership in Myc inhibition builds on 20 years of world-class scientific record, and in just 3 years after the foundation, we closed 2 rounds of equity investments with Venture Capitals. Peptomyc aims at licensing its technology to pharmaceutical companies. Financing through this SME Instrument project will enable us to take to the market our first product, OMO-103 by completing clinical trials and reach a licensing agreement with a pharmaceutical company for full scale production and commercialization. Our results so far show that OMO-103 is: Safer (no toxicity), More efficient (no resistance observed), and More effective (increased survival in lung cancer models). With MYCure, we will take to market our first-in-class Myc inhibitor OMO-103 to treat non-small cell lung cancer, for which the global market is expected to reach 14 bn € by 2023, a total addressable market of which OMO-103 is poised to gain considerable share of up to 15% by 2029 thanks to a sound business plan developed under the SME Instrument.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYCURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYCURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PAROST (2019)

Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.

Read More  

HUD (2018)


Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More